Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
3D Culture/Scaffold

Stem Cell Related Patent Number US7109032

Title:Serum-free medium for mesenchymal stem cells
Inventors:Cancedda, Ranieri; Genoa, Italy
Dozin, Beatrice; Rapallo, Italy
Summary:This invention introduces a serum-free medium for the growth and proliferation of chondrocytes and mesenchymal stem cells in a culture containing growth factors, lipids and fatty acids. Disclosed herein is a medium comprising FGF-2, linoleic acid, ascorbic acid, EGF, PDGFbb, IGF-1, cholesterol, albumin, ?-mercaptoethanol, dexamethasone, insulin and transferrin. For mesenchymal stem cell growth, components are provided which include FGF-2, LIF, SCF, pantothenate, biotin and selenium. Applications are provided for the therapeutic use of such chondrocyte and mesenchymal stem cells cultured in this manner for the repair and reconstitution of cartilage and bone, without the risk of introducing serum pathogens.
Abstract:Serum-free media for growth and proliferation of chondrocytes and mesenchymal stem cells in culture are provided. A serum-free medium for growth of chondrocytes includes a serum-free composition comprising FGF-2, linoleic acid, ascorbic acid, B-mercaptoethanol, transferrin and dexamethasone. Further, the composition comprises EGF, PDGFbb, insulin and albumin. A method for growing chondrocytes in a serum free medium comprising the compostion is also provided. Also provided for mesenchymal stem cell growth, is a serum-free medium which includes a composition comprising FGF-2, LIF, SCF, pantotenate, biotin and selenium and method, therefore.
US Patent Website:Click Here for Full Text of Patent
Title Number:US7109032
Application Number:US2003000614191
Date Filed:08/07/2003
Date Published:19/06/2006
Assignee:Consorzio per la Gestione del Centro di Biotechnologie Avanzate, Genoa, Italy Istituto Nazionale per la Ricerca Sul Cancro, Genoa, Italy

Copyright © 2007 The Institute for Cellular Medicine  10/5/2022